Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Eton Pharmaceuticals Inc (ETON)
Eton Pharmaceuticals Inc (ETON) Actualités

Eton Pharmaceuticals Inc (ETON)

35,70

0,88

(2,53%)

Fermé 29 Juin 10:00PM

35,70

0,08

(0,22%)

Après les heures de négociation: 1:27AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Eton Pharmaceuticals

Schroder International S...

Sangoma Technologies

BNP Paribas Easy Value E...

Multi-Asset Diversified ...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.